Dr. Demetri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Dana-Farber Cancer Institute
Boston, MA 02215Phone+1 617-632-5204Fax+1 617-632-3408- Is this information wrong?
Summary
- Dr. George Demetri is an oncologist in Boston, MA and is affiliated with multiple hospitals affiliated with Harvard Medical School in the area, primarily the Dana-Farber Cancer Institute. He received his medical degree from Stanford University School of Medicine and has been in practice 34 years. He specializes in Sarcomas and Developmental Therapeutics
.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1985 - 1989
University of WashingtonResidency, Internal Medicine, 1983 - 1985
Stanford University School of MedicineClass of 1983
Certifications & Licensure
FL State Medical License 2022 - Present
MA State Medical License 1986 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FASCO) American Society of Clinical Oncologists, 2008
- Whos Who in Medicine and Healthcare Marquis Whos Who
- Super Doctor SuperDoctors.com
Clinical Trials
- Troglitazone in Treating Patients With Liposarcoma Start of enrollment: 1997 Jun 01
- Bexarotene in Treating Patients With Metastatic Breast Cancer Start of enrollment: 1998 Oct 01
- Rosiglitazone in Treating Patients With Liposarcoma Start of enrollment: 1999 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.Sandra P D'Angelo, Dejka M Araujo, Albiruni R Abdul Razak, Mark Agulnik, Steven Attia, Jean-Yves Blay, Irene Carrasco Garcia, John A Charlson, Edwin Choy, George D Dem...> ;Lancet. 2024 Mar 27
- 1 citationsClinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study.Amin H Nassar, Edward El-Am, Ryan Denu, Sarah Abou Alaiwi, Talal El Zarif, Walid Macaron, Noha Abdel-Wahab, Aakash Desai, Caleb Smith, Kaushal Parikh, Muhannad Abbasi,...> ;JACC. Cardiooncology. 2024 Feb 1
- 2 citationsLarotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.Shivaani Kummar, Lin Shen, David S Hong, Ray McDermott, Vicki L Keedy, Michela Casanova, George D Demetri, Afshin Dowlati, Soledad Gallego Melcón, Ulrik N Lassen, Serg...> ;Cancer. 2023 Dec 1
- Join now to see all
Lectures
- First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.2019 ASCO Annual Meeting - 6/1/2019
Other
- Surgical treatment and other localized therapy for metastatic soft tissue sarcomaDemetri GD, Raut CP, George S
http://www.uptodate.com/contents/surgical-treatment-and-other-localized-therapy-for-metastatic-soft-
UpToDate, Wolters Kluwer Health - 2012-07-03 - Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumorsDemetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/adjuvant-and-neoadjuvant-imatinib-for-gastrointestinal-stromal-tumo
UpToDate, Wolters Kluwer Health - 2013-01-15 - Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GISTDemetri GD, Raut CP, Morgan J
http://www.uptodate.com/contents/epidemiology-classification-clinical-presentation-prognostic-featur
UpToDate, Wolters Kluwer Health - 2013-02-04 - Join now to see all
Press Mentions
For New NCI Director, Work Turns Personal: She Is Diagnosed with CancerDecember 14th, 2022- Cancer Combination Therapy Company IDRx Launches with $122M Series a FundingAugust 2nd, 2022
- Sylvester’s Outstanding Faculty for 2022: In Their Own WordsJuly 15th, 2022
- Join now to see all
Grant Support
- Targeted Therapy Resistance Mechanisms In Gastrointestinal Stromal Tumor(Gist)National Cancer Institute2007–2011
Professional Memberships
- Fellow
Hospital Affiliations
Brigham and Women's HospitalBoston, Massachusetts
Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
